Moleculin Biotech, Inc. MBRX
Moleculin Biotech, Inc. (Nasdaq: MBRX) is an oncology drug developer. Its lead program, Annamycin (MIRACLE trial), is in Phase 2 for Relapsed/refractory acute myeloid leukemia (with cytarabine). Its next catalyst on record is Annamycin (MIRACLE): Part A full unblinding (December 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Annamycin (MIRACLE) — Part A full unblinding (December 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Annamycin (MIRACLE) | R/R AML, pivotal Phase 2/3 | small molecule | Phase 2 |
| Annamycin | Soft tissue sarcoma lung metastases / pancreatic cancer Phase 1B/2 | small molecule | Phase 1 |
| WP1066 | Glioblastoma / brain tumors Phase 1B/2 | small molecule | Phase 1 |
| MB-109 / MB-110 | Combination programs | small molecule | Pre-clinical |
Recent results and decisions
- Oct 20, 2026n/a Moleculin Biotech announces a 1-for-20 reverse stock split effective October 20, 2026.
Every 20 shares of the Company's common stock issued and outstanding prior to the opening of trading on October 20, 2026 will be consolidated into one issued and outstanding share.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.